Tamada Koji, Chen Lieping
Department of Dermatology and Oncology, The Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, MD, 21287, USA.
Cancer Immunol Immunother. 2006 Apr;55(4):355-62. doi: 10.1007/s00262-005-0081-y. Epub 2005 Sep 27.
Molecules belonging to the Tumor Necrosis Factor (TNF) and TNF receptor superfamilies have explosively expanded through the era of genomics and bioinformatics. Biological investigations of these molecules have explored their potency as attractive targets for cancer therapy. Anti-tumor mechanisms mediated by TNF superfamily molecules (TNFSF) could be classified into direct actions onto tumor cells and indirect effects through immune or non-immune components of tumor-bearing host. In this review, we focus on TRAIL, CD40, 4-1BB (CD137), and LIGHT as promising molecules to mediate powerful and selective anti-tumor responses, and summarize their unique effector mechanisms. In addition, optimal approaches to manipulate these molecules for cancer therapy are also discussed. We try to provide an insight into a role of TNFSF in cancer therapeutics and highlight each of their potency to be an important player in anti-cancer strategies.
在基因组学和生物信息学时代,属于肿瘤坏死因子(TNF)和TNF受体超家族的分子数量呈爆发式增长。对这些分子的生物学研究探索了它们作为癌症治疗有吸引力靶点的潜力。TNF超家族分子(TNFSF)介导的抗肿瘤机制可分为对肿瘤细胞的直接作用以及通过荷瘤宿主的免疫或非免疫成分产生的间接效应。在本综述中,我们重点关注肿瘤坏死因子相关凋亡诱导配体(TRAIL)、CD40、4-1BB(CD137)和淋巴毒素类似物(LIGHT),它们是介导强大且选择性抗肿瘤反应的有前景的分子,并总结它们独特的效应机制。此外,还讨论了操纵这些分子用于癌症治疗的最佳方法。我们试图深入了解TNFSF在癌症治疗中的作用,并强调它们各自在抗癌策略中成为重要参与者的潜力。